| Similar Articles |
|---|
 |
The Motley Fool
August 1, 2007
Stan Huber |
Fool Exclusive: An Interview With inVentiv Health CEO Eran Broshy Here, the pharmaceutical staffing, sales, and communications provider's CEO discusses the company, its clients and its investment outlook.   |
The Motley Fool
September 29, 2005
Stephen D. Simpson |
Actuant Accentuates the Positive Despite a tough market for cars and recreational vehicles, the specialized hydraulic company still produces solid cash flow. This is exactly the kind of company to look for, just not at this price. |
The Motley Fool
July 17, 2006
Stephen D. Simpson |
Novartis Pays for Its Shopping Spree Expenses from the Chiron acquisition bring down results for the second quarter. Investors, there's a lot to be said for waiting on the right price for even the best stocks out there. |
The Motley Fool
May 8, 2006
Tom Taulli |
24/7 Real Media: Advertiser's Best Friend The global surge in online advertising means big demand for online ad agencies, like 24/7 Real Media. Investors, take note. |
The Motley Fool
May 2, 2006
Stephen D. Simpson |
Still Fishing for Value at Fisher At the right price, this would be an interesting play on health care and biomedical research. Investors, take note. |
The Motley Fool
April 24, 2006
Stephen D. Simpson |
Novartis: A Good Story Repeated Whether sales were a little light or not, this is still a high-quality pharmaceutical company. The company not only has a good pipeline, but the valuation is still attractive without needing to make particularly aggressive assumptions. |
The Motley Fool
August 3, 2004
Jeff Hwang |
Generics Pump Watson The firm's strong growth in generic drug sales eases its branded product pains. The stock is up more than 10%. |
The Motley Fool
July 21, 2006
Brian Lawler |
Gilead's Acquisitive Mood Trading at around 28 times 2006 EPS estimates, and with 40% growth expected for its HIV franchise, Gilead offers tempting value -- assuming it makes smart use of that cash sitting on the balance sheet. |
The Motley Fool
December 14, 2004
Brian Gorman |
Bristol-Myers' Smart Moves Although problems still hang over the company, Bristol-Myers is paving the way for recovery. In the meantime investors will surely be jittery. |
The Motley Fool
June 28, 2004
Jeff Hwang |
Watson Pharmaceuticals Tumbles The generic drug business at Watson Pharmaceuticals is still going strong; it's the branded products that are causing trouble. |
The Motley Fool
January 7, 2004
Rex Moore |
Constellation Brands Shines On The pieces are falling in place for the world's largest wine producer. |
IndustryWeek
March 1, 2005 |
Pharmaceutical Misallocation Some 75% of surveyed pharmaceutical industry executives identified long-term resource allocation as their chief challenge. |
The Motley Fool
July 21, 2004 |
When "Pro Forma" Is Bad Forma Don't let a company you own fool you with "pro forma" numbers. They're gussied-up numbers that companies would prefer you focus on instead of less attractive numbers that are often more accurate representations of their health or performance. |
The Motley Fool
January 27, 2005
Stephen D. Simpson |
Generics Bout Gets Bloody Bristol-Myers Squibb struggles to keep growing amid patent expirations. |
The Motley Fool
April 27, 2006
Stephen D. Simpson |
A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after. |
Registered Rep.
March 1, 2005
David A. Twibell |
What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in. |
The Motley Fool
February 5, 2007
Brian Lawler |
Gilead's Gold Mine In the fourth quarter, the pharmaceutical continues to rake in the cash from its top products. Investors, take note. |
The Motley Fool
November 1, 2004
Brian Gorman |
Bristol-Myers Stays the Course The pharma remains downbeat on its outlook through 2006, but two promising compounds could lift the company's fortunes. |
The Motley Fool
February 27, 2007
Brian Lawler |
Gilead's Green-Lighted Drug Having a diversified drug pipeline is what makes large-cap drug stocks like Gilead so enticing, even to risk-adverse investors. |
The Motley Fool
October 19, 2006
Brian Lawler |
No Gilded Quarter for Gilead The company's recent acquisition may help it become a diversified drug giant. Investors, take note. |
The Motley Fool
February 28, 2007
Brian Lawler |
Worrisome Watson The maker of generic drugs could have a challenging year ahead. Investors, take note. |
The Motley Fool
January 25, 2006
Stephen D. Simpson |
Bristol-Myers Catches a Cold Tough days are coming, but so are promising new drugs. It's understandable why long-term investors might be willing to hold on and see how things work out. |
BusinessWeek
April 25, 2005
Sarah Lacy |
BW50: Gilead's Big Growth Spurt The small biotech rivals the majors in HIV drugs. Now it must expand beyond its niche |
The Motley Fool
May 14, 2007
Rich Smith |
WebSideStory Opens New Chapter While Wall Street went ga-ga over the newly re-named marketing data analyzer's first-quarter pro forma profits, investors should be aware that from a free cash flow perspective, things don't read as nicely. |
The Motley Fool
August 2, 2006
Stephen D. Simpson |
How NICE Is the Growth? Evasive guidance on organic growth should give investors in this Israel-based provider of data, voice, and video analytics solutions reasons to pause. |
The Motley Fool
March 6, 2009
Brian Orelli |
For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations. |
Prepared Foods
July 1, 2005
Marcia Mogelonsky |
Conveniently Organic As organic food products become ever more convenient and perceived health benefits persevere, consumers likely will continue to embrace the category's offerings. |
